Table 2 Study sample split by alveolar volume
From: Prognostic value of alveolar volume in systolic heart failure: a prospective observational study
Alveolar volume (% predicted) | |||||
|---|---|---|---|---|---|
Characteristic | <80 (n = 135) | ≥80 (n = 125) | P-value | ||
Age, years | 71 | (66–77) | 64 | (55–71) | <0.001 |
Male gender | 109 | (81) | 98 | (78) | 0.648 |
BMI, kg/m2 | 26 | (24–29) | 26 | (23–30) | 1.000 |
Current smoker | 21 | (16) | 29 | (23) | 0.157 |
NYHA class III-IV | 57 | (42) | 27 | (22) | <0.001 |
LVEF, % | 30 | (25–38) | 33 | (25–40) | 0.710 |
Cardiothoracic ratio >0.5 | 93 | (69) | 69 | (55) | 0.029 |
NT-ProBNP, pg/mL | 1607 | (811–3878) | 982 | (297–2141) | 0.003 |
Hemoglobin, g/dL | 13.6 | (12.5–14.7) | 13.7 | (12.4–15.0) | 0.552 |
Creatinine, mmol/L | 105 | (82–137) | 97 | (82–114) | 0.139 |
FEV1, % predicted | 78 | (65–87) | 99 | (90–109) | <0.001 |
DLCO, % predicted | 66 | (53–75) | 76 | (68–92) | <0.001 |
COPD | 42 | (31) | 23 | (18) | 0.022 |
Ventilatory restriction | 53 | (39) | 0 | (0) | <0.001 |
Coronary artery disease | 66 | (49) | 49 | (39) | 0.134 |
Hypertension | 75 | (56) | 66 | (53) | 0.709 |
Persistent atrial fibrillation | 34 | (25) | 17 | (14) | 0.020 |
Prior stroke | 10 | (7) | 11 | (9) | 0.821 |
Diabetes | 44 | (33) | 38 | (30) | 0.790 |
Dyslipidemia | 52 | (39) | 57 | (44) | 0.260 |
Beta-blockers | 107 | (79) | 116 | (93) | 0.002 |
ACE-inhibitors | 69 | (51) | 81 | (65) | 0.033 |
Angiotensin receptor antagonists | 40 | (30) | 35 | (28) | 0.786 |
Loop diuretics | 117 | (87) | 108 | (86) | 1.000 |
Potassium sparing drugs | 84 | (62) | 91 | (73) | 0.085 |
Warfarin | 28 | (21) | 14 | (11) | 0.043 |
Implanted pace-maker | 20 | (15) | 15 | (12) | 0.589 |
Implanted defibrillator | 5 | (4) | 8 | (6) | 0.398 |